BCTXZ BriaCell Therapeutics Corp.
Price Chart
Executive Summary
BriaCell Therapeutics Corp. closed a best-efforts offering of 1,449,300 common shares at $3.25 per share, raising gross proceeds of approximately $4.7 million. The offering, conducted via a shelf registration statement, was priced at a discount to the prior close and closed just one day after the 424B5 filing. Proceeds are earmarked for working capital and general corporate purposes, including advancing business objectives.
Key Financial Metrics
Actionable Insight
The rapid close of a dilutive offering at a discount, combined with a tiny market cap and ongoing cash burn, signals acute capital needs. Monitor for further dilution or a potential reverse stock split to maintain Nasdaq listing. The company's cash runway is likely extended only modestly by this raise.
Key Facts
- Offering of 1,449,300 common shares at $3.25 per share closed on June 2, 2026.
- Gross proceeds of approximately $4.7 million before fees and expenses.
- Placement agent ThinkEquity received a 7.5% cash fee and warrants to purchase 72,465 common shares at $4.0625 per share (125% of offering price).
- The offering was priced at a 10.7% discount to the last closing price of $3.64.
- Company is a clinical-stage biotech with no revenue, burning ~$15.6M in net loss over the six months ended January 31, 2026.
- Market cap of the BCTXZ warrant ticker is only ~$1M.
- The offering closed one day after the 424B5 filing, indicating rapid capital raise.
Financial Impact
Gross proceeds of $4.7 million, representing approximately 20% dilution to existing shareholders based on the prior 424B5 analysis.
Risk Factors
- Further dilution from potential future offerings or warrant exercises.
- Nasdaq delisting risk if share price falls below $1.00.
- Clinical-stage company with no revenue and significant cash burn.
- Placement agent warrants (72,465 shares at $4.0625) could add additional overhang.
Market Snapshot
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026953 |
| Exhibit: ex4-1.htm | 0001493152-26-026953 |
| Exhibit: ex5-1.htm | 0001493152-26-026953 |
| Exhibit: ex99-1.htm | 0001493152-26-026953 |
| Exhibit: ex99-2.htm | 0001493152-26-026953 |
| Document: form8-k.htm | 0001493152-26-026953 |
| Document: 0001493152-26-026953-index-headers.html | 0001493152-26-026953 |
| Document: 0001493152-26-026953-index.html | 0001493152-26-026953 |
| Document: 0001493152-26-026953.txt | 0001493152-26-026953 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
10d ago
|
8-K
| $0.1148 $0.1148 | · 0.00% | ▲ +0.40% | $0.1148 (+0.00%) |
|
Jun 2, 2026
10d ago
|
424B5
| $0.1148 $0.1148 | · 0.00% | ▼ −0.69% | $0.1148 (+0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access